References
- Peck WA, Riggs BL, Bell NH, et al. Research directions in osteoporosis. Am J Med 1988: 84(2): 275–82
- Lindsay R, Cosman F. Primary osteoporosis. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992: 831–8
- Cooper C, Melton LJ 3d. Epidemiology of osteoporosis. Trends Endocrinol Metab 1992: 3(6): 224–9
- Solomon L. Bone density in ageing Caucasian and African populations. Lancet 1979: 2(8156–8157): 1326–30
- Pocock NA, Eisman JA, Hopper JL, et al. Genetic determinants of bone mass in adults: a twin study. J Clin Invest 1987: 80(3): 706–10
- Evans RA, Marel GM, Lancaster EK, et al. Bone mass is low in relatives of osteoporotic patients. Ann Intern Med 1988: 109(11): 870–3
- Riggs BL, Melton LJ 3d. Involutional osteoporosis. N Engl J Med 1986: 3l4(26): 1676–86
- Riggs BL, Melton LJ 3d. Clinical heterogeneity of involutional osteoporosis: implications for preventive therapy. J Clin Endocrinol Metab 1990: 70(5): 1229–32
- Christiansen C, Riis BJ, Rødbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987: 1 (8542): 1105–8
- Delmas PD. Biochemical markers of bone turnover: methodology and clinical use in osteoporosis. Am J Med 1991: 91(5B): 59–63S
- Riis BJ. Biochemical markers of bone turnover in diagnosis and assessment of therapy. Am J Med 1991: 91(5B): 64–8S
- Consensus development conference. Prophylaxis and treatment of osteoporosis. Am J Med 1991: 90(1): 107–10
- Eisman JA, Sambrook PN, Kelly PJ, et al. Exercise and its interaction with genetic influences in the determination of bone mineral density. Am J Med 1991: 91(5B): 5–9S
- Grisso JA, Kelsey JL, Strom BL, et al. Risk factors for falls as a cause of hip fracture in women. N Engl J Med 1991: 324(19): 1326–31
- Riggs BL, Melton LJ 3d. The prevention and treatment of osteoporosis. N Engl J Med 1992: 327(9): 620–7
- Carr CJ, Shangraw RF. Nutritional and pharmaceutical aspects of calcium supplementation. Am Pharm 1987: NS27(2): 49–50, 54–7
- Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984: 63(6): 759–63
- Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990: 336(8710): 265–9
- Barrett-Connor E. Risks and benefits of estrogen replacement therapy. In: Mazzaferri EL, Bar RS, Kreisberg RA, eds. Advances in endocrinology and metabolism. Vol 2. St Louis: Mosby—Year Book, 1991: 169–82
- Reginster JY. Effect of calcitonin on bone mass and fracture rates. Am J Med 1991: 91(5B): 19–22S
- Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990: 322(18): 1265–71
- Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990: 323(2): 73–9
- Prior JC. Progesterone as a bone-trophic hormone. Endocrine Rev 1990: 11(2): 386–98